StockWatch
·

AVANTEL LTD. Q1 FY27 Results

AVANTELQ1 FY27 Results
Filing
Result:Good· Market: Flat#Broad based
MetricValue ( Cr)Q4 FY26Q1 FY26
Revenue70.4210.3%35.6%
Total Income70.548.6%35.8%
Expenditure61.847.3%32.5%
PBT8.7018.9%64.1%
Net Profit5.3913.0%67.2%
OPM24.75%3.46pp4.61pp
NPM7.65%0.30pp1.44pp
EPS0.2017.6%66.7%
View full financials

Telecom/defense-electronics revenue grew 35.7% YoY with adjusted PAT up 67.2% and OPM expanding to 24.75% from 20.14%, a healthy core-driven beat though magnitude is aided by a modest base.

Q1 FY-2027 RESULTS · AVANTEL

Avantel Q1: consolidated PAT +67% YoY to ₹5.39 Cr, margins expand on cost leverage

PAT +67.17% YoY · revenue +35.65% · margins expanding

11 Jul 2026 · 3 min read
Revenue

₹70.42 Cr

+35.65% YoY

PAT (consolidated)

₹5.39 Cr

+67.17% YoY

Net margin

7.64%

+1.4pp YoY

EPS

₹0.2

Avantel opened FY27 with its highest-ever quarterly print: consolidated revenue of ₹70.42 Cr, up 35.7% YoY (from ₹51.91 Cr) and 10.3% QoQ, with consolidated PAT of ₹5.39 Cr, up 67.2% YoY (from ₹3.23 Cr) and 13.0% QoQ. Growth is clean — there are no exceptional or one-off items on either side of the comparison, so reported and adjusted YoY are the same. Standalone told a similar growth story (revenue +35.3%, PAT +64.7% YoY to ₹7.62 Cr); the gap between standalone and consolidated PAT is entirely the ₹2.22 Cr quarterly loss at wholly-owned Health Care subsidiary iMeds Global, which added only ₹0.30 Cr of revenue — worth watching but immaterial to group scale.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹70.42 Cr+10.3%+35.7%
Expenses₹61.84 Cr+7.3%+32.5%
PAT₹5.39 Cr+12.98%+67.17%
Net margin7.64%+0.3pp+1.4pp
EPS₹0.2+17.6%+66.7%

Margins expanded on operating leverage, not accounting. EBITDA-basis OPM rose to 24.75% from 20.14% a year ago, and net margin lifted to 7.66% from 6.22%. The swing sits mostly on the materials line: combined cost of materials plus inventory change fell to ~33% of revenue from ~40% a year ago, reflecting capacity that has been capitalised and is now producing. The offsetting pressure is below EBITDA — depreciation rose 61% YoY to ₹7.10 Cr and finance costs more than doubled to ₹1.76 Cr, both direct consequences of the capex cycle. This is the nuance behind the board's own 'OPM compressed by capex' framing: the operating margin actually expanded, but the capex is now flowing through depreciation and interest, capping the drop-through to net profit — most visibly at the consolidated level via the subsidiary drag.

143.88154.92165.95176.99188.03160.2204-1005-1506-1807-2208-21
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹160.22, down 2.6% over the past month of trading.

₹ Cr
02.274.546.816.08Q4 FY25rev ₹49 Cr3.23Q1 FY26rev ₹52 Cr4.27Q2 FY26rev ₹55 Cr4.66Q3 FY26rev ₹51 Cr4.77Q4 FY26rev ₹64 Cr5.39Q1 FY27rev ₹70 Cr
Quarterly consolidated PAT, ₹ Crore

For context: PAT has now risen for 4 consecutive quarters.

The quarter aligns with recent order momentum: Avantel disclosed a ₹20.81 Cr purchase order from L&T on Jul 18, feeding a single-segment defence/satellite communications book (₹70.24 Cr of the ₹70.54 Cr group revenue). Segment assets in Communications jumped to ₹471.6 Cr from ₹340.0 Cr a year ago, confirming the capex build. Concurrent board actions were governance-only — director re-appointments (Abburi Siddhartha Sagar, Vyasabhattu Ramchander), appointment of Peddi Bala Bhaskar Rao as Director (Operations), and committee reconstitution — with no bearing on the numbers. Avantel gives no formal guidance and, as a micro/small-cap, carries no published brokerage consensus for the quarter; commentary that exists (MarketsMojo, Business Standard) is post-result and notes the stock trades at a rich ~320x trailing earnings, so the print's quality matters more than its beat/miss status.

  • W1

    Depreciation and finance cost trajectory — ₹7.10 Cr and ₹1.76 Cr this quarter; whether rising capex charges keep capping net drop-through as OPM expands

  • W2

    iMeds Global (Health Care) turnaround — ₹2.22 Cr loss on ₹0.30 Cr revenue this quarter; the drag on consolidated PAT

  • W3

    Order-book conversion — execution of the ₹20.81 Cr L&T order and further defence/satellite wins feeding the single-segment book

Informational and educational content only. Not investment advice.